Latest Articles

Publication Date
Residual hemostatic material (Surgicel) mimicking endometriosis: a case report of gossypiboma.

Gossypiboma, the unintentional retention of surgical materials, is a rare but significant postoperative complication. While most of the literature focuses on retained sponges, absorbable hemostatic agents such as Surgicel may …

Published: Aug. 7, 2026, midnight
EGF as a non-invasive biomarker of endometriosis: a case control study.

Endometriosis is a chronic inflammatory condition that affects an estimated 1 in 10 women but is often mis- and underdiagnosed due to its non-specific symptoms and the lack of a …

Published: July 29, 2026, midnight
Benign Metastasizing Leiomyoma With Myomatous Erythrocytosis Syndrome: First Reported Coexistence as a Unified Hormonal Syndrome.

Benign metastasizing leiomyoma (BML) is a rare condition characterized by histologically benign smooth muscle tumours arising at extrauterine sites, most commonly the lungs, in women with a history of uterine …

Published: July 15, 2026, midnight
Maximising and Maintaining Fertility in Suspected or Confirmed Endometriosis: A Structured Narrative Review for Clinical Practice.

Endometriosis affects a substantial proportion of women of reproductive age and is a common, often under-recognised contributor to subfertility. Its effects on fertility are multifactorial, and both the disease and …

Published: July 9, 2026, midnight
PRT-064040: A nasal spray of novel, potent, and selective calcitonin gene-related peptide receptor antagonist for migraine.

Calcitonin gene-related peptide (CGRP), a neuropeptide, has been implicated in autoimmune diseases, endometriosis, tumors, and primary headaches, including migraine. The development of a novel, fast-acting CGRP receptor antagonist administered via …

Published: June 17, 2026, midnight
Endometriosis and ovarian cancer: epidemiological evidence, molecular insights, and clinical decision-making.

Endometriosis, particularly ovarian endometrioma, is associated with a 2-fold increased risk of ovarian cancer (OC), especially the clear cell and endometrioid subtypes. However, the absolute lifetime risk of OC in …

Published: May 17, 2026, midnight
Electrospun Cellulose Acetate Nanofibers for Healthcare Products: Towards Sensing Pads for Endometriosis.

The need for reliable preventive medicine tools is growing, especially for diseases with long diagnostic delays, such as endometriosis, which can take several years to diagnose. In this context, cellulose …

Published: April 24, 2026, midnight
Novel Insights into the Pathogenic Role of CSF1R in Endometriosis.

Endometriosis (EM) is a prevalent gynecological disorder linked to pelvic pain, menstrual disturbances, and infertility. Despite its clinical burden, the molecular mechanisms underlying EM remain elusive, necessitating the discovery of …

Published: April 14, 2026, midnight
From Endometriosis to Endometriosis-Associated Ovarian Cancer: Molecular Mechanisms, Risk Stratification and Clinical Implications.

Endometriosis is a chronic estrogen-dependent disorder affecting approximately 10% of women of reproductive age. Increasing epidemiological and molecular evidence indicates that it may represent a precursor condition for a subset …

Published: April 14, 2026, midnight
Single-Dose Bioequivalence Study of Elagolix Tablets 200 mg (Test Product) and Elagolix Tablets 200 mg (Reference Product) in Healthy Non-Pregnant, Non-Lactating Premenopausal Female Subjects Under Fasting Conditions.

Elagolix is a short-acting oral gonadotropin-releasing hormone antagonist utilized for treating endometriosis-associated pain by rapidly suppressing gonadotropins and estradiol. Although well characterized in Western populations, clinical data regarding its use …

Published: April 2, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!